Similar articles

• Tumor-infiltrating lymphocytes from human solid tumors: antigen-specific killer T lymphocytes of activated natural killer lymphocytes.

  Whiteside TL, Heo DS, Takagi S, Herberman RB. Whiteside TL, et al. Immunol Ser. 1989;48:139-57. Immunol Ser. 1989. PMID: 2488318 No abstract available.
• Therapy with interleukin-2 and tumor-derived activated lymphocytes.

  Oldham RK. Oldham RK. Immunol Ser. 1994;61:251-71. Immunol Ser. 1994. PMID: 8011748 Review. No abstract available.
• Adoptive immunotherapy with recombinant interleukin 2, LAK and TIL.

  Kurnick JT, Kradin RL. Kurnick JT, et al. Allergol Immunopathol (Madr). 1991 Sep-Oct;19(5):209-14. Allergol Immunopathol (Madr). 1991. PMID: 1811418 Review. No abstract available.
• Adoptive cellular immunotherapy of cancer.

  Winter H, Fox BA. Winter H, et al. Curr Opin Mol Ther. 1999 Feb;1(1):89-97. Curr Opin Mol Ther. 1999. PMID: 11249690 Review. No abstract available.
• Interleukin 2 in cancer therapy.

  Testa U, Montesoro E, Bulgarini D, Samoggia P, Masciulli R, Habetswallner D, Carè A, Mariani G, Giannella G, Boccoli G, et al. Testa U, et al. Ann Ist Super Sanita. 1990;26(3-4):283-334. Ann Ist Super Sanita. 1990. PMID: 2091501 Review.